Patients With Melanoma Metastases at Cutaneous and Subcutaneous Sites Are Highly Susceptible to Interleukin-2-Based Therapy

Journal of Immunotherapy

Volumn 24, Issue 1, 2001, Pages 88-90

  Chang, Eugene ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; SCHOOL CHILD; SKIN METASTASIS; TUMOR REGRESSION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHILD; DEMOGRAPHY; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0035134678     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200101000-00010     Document Type: Article

References (3)

1. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 183 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994; 271:907-13.
2. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2. Ann Surg 1998; 228:307-19.
3. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998; 4:321-7.